Adipose tissue and ceramide biosynthesis in the pathogenesis of obesity

Advances in Experimental Medicine and Biology

Volumn 721, Issue , 2011, Pages 67-86

  Samad, Fahumiya ^a   Badeanlou, Leylla ^a   Shah, Charmi ^a   Yang, Guang ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; CERAMIDE; CYCLOOXYGENASE 2; FATTY ACID; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; SPHINGOSINE 1 PHOSPHATE; THERMOZYMOCIDIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ARTICLE; ATHEROSCLEROSIS; BIOSYNTHESIS; BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASE; CYTOKINE PRODUCTION; ENERGY METABOLISM; GENE EXPRESSION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPID STORAGE; MARKER GENE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SOCS 3 GENE; WEIGHT REDUCTION;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; CARDIOVASCULAR DISEASES; CERAMIDES; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIETARY FATS; DISEASE MODELS, ANIMAL; FATTY ACIDS; FATTY LIVER; HUMANS; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; OXIDATIVE STRESS; SPHINGOLIPIDS;

EID: 80053586168     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0650-1_5     Document Type: Article

References (161)

1. Ogden CL, Carroll MD, Curtin LR et al. Prevalence ofoverweight and obesity in the United States, 1999-2004. JAMA 2006; 295(13):1549-55.
2. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444(7121):860-7. (Pubitemid 46024993)
3. Hotamisligil GS. Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord 2000; 24(Suppl 4):S23-S27.
4. Mohamed-Ali V, Goodrick S, Rawesh A et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82:4196-200. (Pubitemid 27525539)
5. Christiansen T, Richelsen B, Bruun JM. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes (Lond) 2005; 29(1):146-50. (Pubitemid 40065478)
6. Bruun JM, Pedersen SB, Richelsen B. Regulation of interleukin 8 production and gene expression in human adipose tissue in vitro. J Clin Endocrinol Metab 2001; 86(3):1267-73. (Pubitemid 32323015)
7. Wellen KE, Hotamisligil GS. Inflammation, stress and diabetes. J Clin Invest2005; 115(5):llll-9.
8. Fantuzzi G. Adipose tissue, adipokines and inflammation. J Allergy Clin Immunol 2005; 115(5):911-9.
9. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25(1):4-7. (Pubitemid 38032801)
10. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003; 27(Suppl 3):S53-S55. (Pubitemid 38019190)
11. Neels JG, Badeanlou L, Hester KD et al. Keratinocyte-derived Chemokine in Obesity: Expression and role in adipose macrophage infiltration and glucose homeostasis. J Biol Chem 2009.
12. Delias C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93(4):631-40. (Pubitemid 40485397)
13. Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996; 2:568-82. (Pubitemid 26353106)
14. Juhan-Vague I, Alessi MC, Mavri A et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1:1575-9.
15. Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: Studies of PAI-1. Arterioscler Thromb Vasc Biol 1998; 18:1-6. (Pubitemid 28047591)
16. Eriksson P, Reynisdottir S, Lonnqvist F et al. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 1998; 41:65-71. (Pubitemid 28105743)
17. Loskutoff DJ, Ihara H, Yamamoto K, et al. The fat mouse: A powerful genetic model to study alterations in hemostatic gene expression in obesity. In: Suzuki K, Ikeda Y, Maruyama I, eds. New Frontier in Vascular Biology; Thrombosis and Hemostasis. Osaka: Eibun Press, Inc., 2000:151-60.
18. De TB, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 2005; 5(2):149-54. (Pubitemid 40378745)
19. Schafer K, Fujisawa K, Konstantinides S et al. Disruption of the plasminogen activator inhibitor-1 gene reduces the adiposity and improves the metabolic profile of geneticallly obese and diabetic ob/ob mice. FASEBJ2001; (June 27, 2001) 10.1096/fj.00-0750fje.
20. Ma L-J, Mao S-L, Taylor KL et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 53:336-46. (Pubitemid 38174548)
21. Kraegen EW, Cooney GJ, Ye JM et al. The role of lipids in the pathogenesis of muscle insulin resistance and beta cell failure in type II diabetes and obesity. Exp Clin Endocrinol Diabetes 2001; 109(Suppl 2):S189-S201. (Pubitemid 32577582)
22. Lelliott C, Vidal-Puig AJ. Lipotoxicity, an imbalance between lipogenesis de novo and fatty acid oxidation. Int J Obes Relat Metab Disord 2004; 28(Suppl 4):S22-S28. (Pubitemid 40143845)
23. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinol 2003; 144(12):5159-65. (Pubitemid 37476041)
24. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51(1):7-18.
25. Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 2006; 45(1):42-72. (Pubitemid 43170804)
26. Hanada K. Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism. Biochim Biophys Acta 2003; 1632(1-3):16-30. (Pubitemid 36628112)
27. Futerman AH, Hannun YA. The complex life ofsimple sphingolipids. EMBO Rep 2004; 5(8):777-82.
28. Hannun YA, Obeid LM. The ceramide-centric universe of lipid-mediated cell regulation: Stress encounters ofthe lipid kind. J Biol Chem 2002; 277:25847-50. (Pubitemid 34967060)
29. Pewzner-Jung Y, Ben-Dor S, Futerman AH. When do Lasses (longevity assurance genes) become CerS (ceramide synthases)?: Insights into the regulation of ceramide synthesis. J Biol Chem 2006; 281(35):25001-5. (Pubitemid 44401887)
30. Sugiura M, Kono K, Liu H et al. Ceramide kinase, a novel lipid kinase. Molecular cloning and functional characterization. J Biol Chem 2002; 277:23294-300. (Pubitemid 34952158)
31. Hirabayashi Y, Osuka S, Nagatsuka Y. [Biology of glucosylceramide synthase: importance of lipid glycosylation]. Tanpakushitsu Kakusan Koso 2003; 48(8 Suppl):958-62.
32. Samad F, Hester KD, Yang G et al. Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes 2006; 55(9):2579-87. (Pubitemid 44871159)
33. Holland WL, Brozinick JT, Wang LP et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat- and obesity-induced insulin resistance. Cell Metab 2007; 5(3):167-79.
34. Shah C, Yang G, Lee I, et al. Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. J Biol Chem 2008; 283(20):13538-48.
35. Haus JM, Kashyap SR, Kasumov T et al. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 2009; 58(2):337-43.
36. Gorska M, Dobrzyn A, Baranowski M. Concentrations of sphingosine and sphinganine in plasma of patients with type 2 diabetes. Med Sci Monit 2005; 11(1):CR35-CR38. (Pubitemid 40116398)
37. Kolak M, Westerbacka J, Velagapudi VR et al. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007; 56(8):1960-8. (Pubitemid 47195815)
38. Wu D, Ren Z, Pae M et al. Aging up-regulates expression of inflammatory mediators in mouse adipose tissue. J Immunol 2007; 179(7):4829-39.
39. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor a: A key component of the obesity-diabetes link. Diabetes 1994; 43:1271-8.
40. Chavez JA, Summers SA. Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch Biochem Biophys 2003; 419(2):101-9. (Pubitemid 37329976)
41. MichailidouZ, Jensen MD, Dumesic DA et al. Omental llbeta-hydroxysteroid dehydrogenase 1 correlates with fat cell size independently of obesity. Obesity (Silver Spring) 2007; 15(5):1155-63. (Pubitemid 46932470)
42. Kotelevtsev Y, Holmes MC, Burchell A et al 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 1997; 94(26):14924-9. (Pubitemid 28041476)
43. Masuzaki H, Paterson J, Shinyama H et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294(5549):2166-70. (Pubitemid 33150673)
44. Masuzaki H, Yamamoto H, Kenyon CJ et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003; 112(1):83-90. (Pubitemid 38056379)
45. Arai N, Masuzaki H, Tanaka T et al. Ceramide and adenosine 5'-monophosphate-activated protein kinase are two novel regulators of llbeta-hydroxysteroid dehydrogenase type 1 expression and activity in cultured preadipocytes. Endocrinol 2007; 148(11):5268-77. (Pubitemid 350012641)
46. Murray DK, Ruhmann-Wennhold A, Nelson DH. Dexamethasone effect on the phospholipid content of isolated fat cell ghosts from adrenalectomized rats. Endocrinol 1979; 105(3):774-7. (Pubitemid 9257470)
47. Johnston D, Matthews ER, Melnykovych G. Glucocorticoid effects on lipid metabolism in HeLa cells: inhibitionofcholesterol synthesis and increased sphingomyelinsynthesis. Endocrinol 1980; 107(5):1482-8. (Pubitemid 10029743)
48. Murray DK, Ruhmann-Wennhold A, Nelson DH. Adrenalectomy decreases the sphingomyelin and cholesterol content of fat cell ghosts. Endocrinol 1982; lll(2):452-5.
49. Evans JL, Goldfine ID, Maddux BA et al. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002; 23(5): 599-622. (Pubitemid 35191625)
50. Furukawa S, Fujita T, Shimabukuro M et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114(12):1752-61. (Pubitemid 40385531)
51. Gregor MF, Hotamisligil GS. Thematic review series: Adipocyte Biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J Lipid Res 2007; 48(9):1905-14. (Pubitemid 47360610)
52. Martinez JA. Mitochondrial oxidative stress and inflammation: an slalom to obesity and insulin resistance. J Physiol Biochem 2006; 62(4):303-6. (Pubitemid 46938959)
53. Andrieu-Abadie N, Gouaze V, Salvayre R et al. Ceramide in apoptosis signaling: relationship with oxidative stress. Free Radic Biol Med 2001; 31(6):717-28. (Pubitemid 32835252)
54. Birbes H, el BS, Obeid LM et al. Mitochondria and ceramide: intertwined roles in regulation of apoptosis. Adv Enzyme Regul 2002; 42:113-29. (Pubitemid 35033533)
55. Novgorodov SA, Szulc ZM, Luberto C et al. Positively charged ceramide is apotent inducer ofmitochondrial permeabilization. J Biol Chem 2005; 280(16):16096-105. (Pubitemid 40616734)
56. Kashkar H, Wiegmann K, Yazdanpanah B et al. Acid sphingomyelinase is indispensable for UV light-induced Bax conformational change at the mitochondrial membrane. J Biol Chem 2005; 280(21):20804-13. (Pubitemid 40776785)
57. Birbes H, Luberto C, Hsu YTet al. A mitochondrial pool ofsphingomyelin is involved in TNFalpha-induced Bax translocation to mitochondria. Biochem J 2005; 386(Pt 3):445-51. (Pubitemid 40445868)
58. Sharpe JC, Arnoult D, Youle RJ. Control of mitochondrial permeability by Bcl-2 family members. Biochim Biophys Acta 2004; 1644(2-3):107-13. (Pubitemid 38281267)
59. Zhang Y, Proenca R, Maffei M et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372:425-32. (Pubitemid 24365442)
60. Friedman JM, Halaas JL. Leptin and the regulation ofbody weight in mammals. Nature 1998; 395:763-70. (Pubitemid 28485436)
61. Friedman JM, Leibel RL. Tackling a weighty problem. Cell 1992; 69:217-20.
62. Hamann A, Matthaei S. Regulation of energy balance by leptin. Exper and Clin Endocrin and Diabetes 1996; 104:293-300. (Pubitemid 26306120)
63. Van Heek M, Compton DS, France CF et al. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 1997; 99:385-90. (Pubitemid 27414794)
64. Heymsfield SB, Greenberg AS, FujiokaKet al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282:1568-75. (Pubitemid 29504050)
65. Prpic V, Watson PM, Frampton IC et al. Differential mechanisms and development of leptin resistance in A/J versus C57BL/6J mice during diet-induced obesity. Endocrinol 2003; 144(4):1155-63. (Pubitemid 36428455)
66. Wang MY, Orci L, Ravazzola M et al. Fat storage in adipocytes requires inactivation of leptin's paracrine activity: implications for treatment of human obesity. Proc Natl Acad Sci USA 2005; 102(50):18011-6. (Pubitemid 41798493)
67. Hojjati MR, Li Z, Zhou H et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem 2005; 280(ll):10284-9. (Pubitemid 40395884)
68. Park TS, Panek RL, Mueller SB et al. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2004; 110(22):3465-71. (Pubitemid 39602225)
69. Yang GD, Badeanlou L, Bielawski JD et al. Central role of ceramide biosynthesis in body weight regulation, energy metabolism and the metabolic syndrome. Am J Physiol Endocrinol Metab 2009.
70. Kanatani Y, Usui I, Ishizuka K et al. Effects ofpioglitazone on suppressor ofcytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression. Diabetes 2007; 56(3):795-803. (Pubitemid 46348484)
71. Howard JK, Flier JS. Attenuation of leptin and insulin signaling by SOCS proteins. Trends Endocrinol Metab 2006; 17(9):365-71. (Pubitemid 44596259)
72. Steinberg GR, McAinch AJ, Chen MB et al. The suppressor of cytokine signaling 3 inhibits leptin activation of AMP-kinase in cultured skeletal muscle of obese humans. J Clin Endocrinol Metab 2006; 91(9):3592-7. (Pubitemid 44402142)
73. Cernkovich ER, Deng J, Bond MC et al. Adipose-specific disruption of signal transducer and activator of transcription 3 increases body weight and adiposity. Endocrinol 2008; 149(4):1581-90. (Pubitemid 351468313)
74. Wang ZW, Pan WT, LeeYet al. The role of leptin resistance in the lipid abnormalities of aging. FASEB J 2001; 15(1):108-14. (Pubitemid 32061661)
75. OrciL, CookWS, Ravazzola M et al. Rapid transformation of white adipocytes into fat-oxidizing machines. Proc Natl Acad Sci USA 2004; 101(7):2058-63. (Pubitemid 38229014)
76. Park BH, Wang MY, Lee Y et al. Combined leptin actions on adipose tissue and hypothalamus are required to deplete adipocyte fat in lean rats: implications for obesity treatment. J Biol Chem 2006; 281(52):40283-91. (Pubitemid 46041833)
77. Unger RH, Zhou YT, Orci L. Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc Natl Acad Sci USA 1999; 96(5):2327-32. (Pubitemid 29117914)
78. Martin TL, Alquier T, Asakura K et al. Diet-induced obesity alters AMP kinase activity in hypothalamus and skeletal muscle. J Biol Chem 2006; 281(28):18933-41. (Pubitemid 44035396)
79. Nicholls DG, Locke RM. Thermogenic mechanisms in brown fat. Physiol Rev 1984; 64(l):l-64.
80. Shimeno H, Soeda S, Sakamoto M et al. Partial purification and characterization ofsphingosine N-acyltransferase (ceramide synthase) from bovine liver mitochondrion-rich fraction. Lipids 1998; 33(6):601-5. (Pubitemid 28283711)
81. Santana P, Pena LA, Haimovitz-Friedman A et al. Acid sphingomyelinase- deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 1996; 86(2):189-99. (Pubitemid 26286102)
82. Bionda C, Portoukalian J, Schmitt D et al. Subcellular compartmentalization of ceramide metabolism: MAM (mitochondria-associated membrane) and/or mitochondria?. Biochem J 2004; 382(Pt 2):527-33. (Pubitemid 39243919)
83. Garcia-Ruiz C, Colell A, Mari M et al. Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species. Role of mitochondrial glutathione. J Biol Chem 1997; 272(17):11369-77. (Pubitemid 27184141)
84. Soeda S, Honda O, Shimeno H et al. Sphingomyelinase and cell-permeable ceramide analogs increase the release ofplasminogen activator inhibitor-1 from cultured endothelial cells. Thromb Res 1995; 80(6):509-18.
85. Kimura M, Soeda S, Oda M et al. Release of plasminogen activator inhibitor-1 from human astrocytes is regulated by intracellular ceramide. J Neurosci Res 2000; 62:781-8.
86. Holland WL, Summers SA. Sphingolipids, insulin resistance and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev 2008; 29(4):381-402. (Pubitemid 351831506)
87. Summers SA, Garza LA, Zhou H et al. Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol Cell Biol 1998; 18:5457-64. (Pubitemid 28388128)
88. Nelson DH, Murray DK. Sphingolipids inhibit insulin and phorbol ester stimulated uptake of 2-deoxyglucose. Biochem Biophys Res Commun 1986; 138(1):463-7. (Pubitemid 16053472)
89. Hajduch E, Balendran A, Batty IH et al. Ceramide impairs the insulin-dependent membrane recruitment of protein kinase B leading to a loss in downstream signalling in L6 skeletal muscle cells. Diabetologia 2001; 44(2):173-83. (Pubitemid 32156201)
90. Summers SA, Yin VP, Whiteman EL et al. Signaling pathways mediating insulin-stimulated glucose transport. Ann NY Acad Sci 1999; 892:169-86.
91. LiuP,LefflerBJ, Weeks LK et al. Sphingomyelinase activates GLUT4translocation viaacholesterol-dependent mechanism. Am J Physiol Cell Physiol 2004; 286(2):C317-C329. (Pubitemid 38146355)
92. Summers SA, Kao AW, Kohn AD et al. The role of glycogen synthase kinase 3beta in insulin-stimulated glucose metabolism. J Biol Chem 1999; 274(25):17934-40.
93. Kralik SF, Liu P, Leffler BJet al. Ceramide and glucosamine antagonism of alternate signalingpathways regulating insulin- and osmotic shock-induced glucose transporter 4 translocation. Endocrinol 2002; 143(1):37-46. (Pubitemid 34056401)
94. PazK, HemiR,LeRoithDet al. Amolecularbasisforinsulinresistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to thejuxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 1997; 272(47):29911-8.
95. Kanety H, Hemi R, Papa MZ et al. Sphingomyelinase and ceramide suppress insulin-induced tyrosine phosphorylation of the insulin receptor substrate-1. J Biol Chem 1996; 271(17):9895-7. (Pubitemid 26131541)
96. Chavez JA, Knotts TA, Wang LP et al. A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J Biol Chem 2003; 278(12):10297-303. (Pubitemid 36800291)
97. BourbonNA, SandirasegaraneL, KesterM. Ceramide-induced inhibition of Akt is mediatedthroughprotein kinase Czeta: implications for growth arrest. J Biol Chem 2002; 277(5):3286-92. (Pubitemid 34953194)
98. Salinas M, Lopez-Valdaliso R, Martin D et al. Inhibition of PKB/Aktl by C2-ceramide involves activation of ceramide-activated protein phosphatase in PC12 cells. Mol Cell Neurosci 2000; 15(2):156-69. (Pubitemid 30109119)
99. Schubert KM, Scheid MP, Duronio V. Ceramide inhibits protein kinase B/Akt by promoting dephosphorylation ofserine. J Biol Chem 2000; 275(18):13330-5. (Pubitemid 30257390)
100. Stratford S, DeWald DB, Summers SA. Ceramide dissociates 3'-phosphoinositide production from pleckstrin homology domain translocation. Biochem J 2001; 354(Pt 2):359-68. (Pubitemid 32209874)
101. Stratford S, Hoehn KL, Liu F et al. Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J Biol Chem 2004; 279(35):36608-15. (Pubitemid 39129005)
102. Teruel T, Hernandez R, Lorenzo M. Ceramide mediates insulin resistance by tumor necrosis factor-alpha in brown adipocytes by maintaining Akt in an inactive dephosphorylated state. Diabetes 2001; 50:2563-71. (Pubitemid 33642775)
103. Zhou H, Summers SA, Birnbaum MJ et al. Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis. J Biol Chem 1998; 273(26):16568-75. (Pubitemid 28311444)
104. Dobrowsky RT, Kamibayashi C, Mumby MC et al. Ceramide activates heterotrimeric protein phosphatase 2A. J Biol Chem 1993; 268(21):15523-30. (Pubitemid 23222045)
105. Resjo S, Goransson O, Harndahl L et al. Protein phosphatase 2A is the main phosphatase involved in the regulation of protein kinase B in rat adipocytes. Cell Signal 2002; 14(3):231-8. (Pubitemid 34102452)
106. Powell DJ, Hajduch E, Kular G et al. Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism. Mol Cell Biol 2003; 23(21):7794-808. (Pubitemid 37271476)
107. Powell DJ, Turban S, Gray A et al. Intracellular ceramide synthesis and protein kinase Czeta activation play an essential role in palmitate-induced insulin resistance in rat L6 skeletal muscle cells. Biochem J 2004; 382(Pt 2):619-29. (Pubitemid 39243928)
108. Yuan M, Konstantopoulos N, Lee J et al. Reversal of obesity- and diet-induced insulin resistance with salicylates ortargeted disruption oflkkbeta. Science 2001; 293(5535):1673-7. (Pubitemid 32807849)
109. Hirosumi J, Tuncman G, Chang L et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420(6913):333-6. (Pubitemid 35398190)
110. Ruvolo PP. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol Res 2003; 47(5):383-92. (Pubitemid 36379200)
111. Tagami S, Inokuchi J, Kabayama K et al. Ganglioside GM3 participates in the pathological conditions of insulin resistance. J Biol Chem 2002; 277:3085-92. (Pubitemid 34953168)
112. Kabayama K, Sato T, Kitamura F et al. TNFalpha-induced insulin resistance in adipocytes as a membrane microdomain disorder: involvement of ganglioside GM3. Glycobiology 2005; 15(l):21-9. (Pubitemid 40202036)
113. Aerts JM, Ottenhoff R, Powlson AS et al. Pharmacological inhibition of glucosylceramide synthesis enhances insulin sensitivity. Diabetes 2007.
114. Yamashita T, Hashiramoto A, Haluzik M et al. Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc Natl Acad Sci USA 2003; 100(6):3445-9. (Pubitemid 36356603)
115. Donnelly KL, Smith CI, Schwarzenberg SJ et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115(5):1343-51. (Pubitemid 40629054)
116. Greco D, Kotronen A, Westerbacka J et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol 2008; 294(5):G1281-G1287.
117. Yetukuri L, Katajamaa M, Medina-Gomez G et al. Bioinformatics strategies for lipidomics analysis: characterization of obesity related hepatic steatosis. BMC Syst Biol 2007; 1:12.
118. Kotronen A, Seppanen-Laakso T, Westerbacka J et al. Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 2009; 58(1):203-8.
119. Deevska GM, Rozenova KA, Giltiay NV et al. Acid Sphingomyelinase Deficiency Prevents Diet-induced Hepatic Triacylglycerol Accumulation and Hyperglycemia in Mice. J Biol Chem 2009; 284(13):8359-68.
120. Ueki K, Kondo T, Tseng YH et al. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance and the metabolic syndrome in the mouse. Proc Natl Acad Sci USA 2004; 101(28):10422-7. (Pubitemid 38924941)
121. Krauss RM, Winston M, Fletcher RN et al. Obesity: impact of cardiovascular disease. Circulation 1998; 98(14):1472-6.
122. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox and impact ofweight loss. J Am Coll Cardiol 2009; 53(21):1925-32.
123. Vaughan DE. Plasminogen activator inhibitor-1: A common denominator in cardiovascular disease. J Invest Med 1998; 46:370-6. (Pubitemid 128455006)
124. Chatterjee S. Sphingolipids in atherosclerosis and vascular biology. Arterioscler Thromb Vasc Biol 1998; 18(10):1523-33. (Pubitemid 28465402)
125. Auge N, Negre-Salvayre A, Salvayre R et al. Sphingomyelin metabolites in vascular cell signaling and atherogenesis. Prog Lipid Res 2000; 39(3):207-29. (Pubitemid 30224704)
126. Li H, Junk P, Huwiler A et al. Dual effect of ceramide on human endothelial cells: induction of oxidative stress andtranscriptionalupregulationofendothelial nitric oxide synthase. Circulation 2002; 106(17):2250-6. (Pubitemid 35222221)
127. Auge N, Maupas-Schwalm F, Elbaz M et al. Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation ofthesphingomyelin/ceramidepathway and smoothmuscle cell proliferation. Circulation 2004; 110(5):571-8. (Pubitemid 39031175)
128. Nixon GF, Mathieson FA, Hunter I. The potential roles of sphingolipids in vascular smooth-muscle function. Biochem Soc Trans 2007; 35(Pt 5):908-9. (Pubitemid 350206393)
129. Li Z, Basterr MJ, Hailemariam TK et al. The effect of dietary sphingolipids on plasma sphingomyelin metabolism and atherosclerosis. Biochim Biophys Acta 2005; 1735(2):130-4. (Pubitemid 40961968)
130. Jiang XC, Paultre F, Pearson TA et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2000; 20:2614-8.
131. Paumen MB, Ishida Y, Muramatsu M et al. Inhibition of carnitine palmitoyltransferase I augments sphingolipid synthesis and palmitate-induced apoptosis. J Biol Chem 1997; 272(6):3324-9.
132. De Vries JE, Vork MM, Roemen TH et al. Saturated but not mono-unsaturated fatty acids induce apoptotic cell death in neonatal rat ventricular myocytes. J Lipid Res 1997; 38(7):1384-94. (Pubitemid 27332565)
133. Dyntar D, Eppenberger-Eberhardt M, Maedler K et al. Glucose and palmitic acid induce degeneration of myofibrils and modulate apoptosis in rat adult cardiomyocytes. Diabetes 2001; 50(9):2105-13. (Pubitemid 33643679)
134. Ren J, Relling DP. Leptin-induced suppression of cardiomyocyte contraction is amplified by ceramide. Peptides 2006; 27(6):1415-9. (Pubitemid 43766991)
135. Marathe S, Choi Y, Leventhal AR et al. Sphingomyelinase converts lipoproteins from apolipoprotein E knockout mice into potent iducers of macrophage foam cell formation. Arterioscler Thromb Vasc Biol 2000; 20:2607-13.
136. Schissel SL, Tweedie-Hardman J, Rapp JH et al. Tabas I. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest 1996; 98(6):1455-64. (Pubitemid 26322072)
137. Mitchinson MJ, Hardwick SJ, Bennett MR. Cell death in atherosclerotic plaques. Curr Opin Lipidol 1996; 7(5):324-9. (Pubitemid 26372453)
138. MallatZ, Tedgui A. Apoptosis in the vasculature: mechanisms and functional importance. Br J Pharmacol 2000; 130(5):947-62. (Pubitemid 30453528)
139. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003; 4(5):397-407. (Pubitemid 36565571)
140. Alewijnse AE, Peters SL, Michel MC. Cardiovascular effects of sphingosine-l-phosphate and other sphingomyelin metabolites. Br J Pharmacol 2004; 143(6):666-84. (Pubitemid 39611603)
141. Yatomi Y, Ohmori T, Rile G et al. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood 2000; 96(10):3431-8.
142. MurataN, Sato K, Kon Jet al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J 2000; 352 Pt 3:809-15. (Pubitemid 32015038)
143. Nofer JR, van der GM, Tolle M et al. HDL induces NO-dependent vasorelaxation viathe lysophospholipid receptor S1P3. J Clin Invest 2004; 113(4):569-81. (Pubitemid 38542506)
144. Karliner JS. Toward solving the riddle: the enigma becomes less mysterious. Circ Res 2006; 99(5):465-7. (Pubitemid 44337817)
145. Auge N, Nikolova-Karakashian M, Carpentier S et al. Role of sphingosine 1-phosphate in the mitogenesis induced by oxidized low density lipoprotein in smooth muscle cells via activation of sphingomyelinase. ceramidase and sphingosine kinase. J Biol Chem 1999; 274(31):21533-8.
146. Ipatova OM, Torkhovskaya TI, Zakharova TS et al. Sphingolipids and cell signaling: involvement in apoptosis and atherogenesis. Biochemistry (Mosc) 2006; 71(7):713-22. (Pubitemid 44092034)
147. Xia P, Gamble JR, Rye KA et al. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci USA 1998; 95(24):14196-201. (Pubitemid 28549344)
148. Bot M, Nofer JR, vanBerkel TJC et al. Lysophospholipids: two-faced mediators in atherosclerosis. Future Lipidol 2007; 2(3): 341-56. (Pubitemid 46916284)
149. Karliner JS, Honbo N, Summers K et al. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2001; 33(9):1713-7. (Pubitemid 32844228)
150. Jin ZQ, Zhou HZ, Zhu P et al. Cardioprotection mediated by sphingosine-l-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am J Physiol Heart Circ Physiol 2002; 282(6):H1970-H1977. (Pubitemid 34663002)
151. Lecour S, Smith RM, Woodward B et al. Identification of anovel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 2002; 34(5):509-18.
152. Nofer JR, Assmann G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc Med 2005; 15(7):265-71. (Pubitemid 41437910)
153. Kimura T, Sato K, Kuwabara A et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem 2001; 276(34):31780-5.
154. Kimura T, Sato K, Malchinkhuu E et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler Thromb Vasc Biol 2003; 23(7):1283-8. (Pubitemid 36871285)
155. Nofer JR, Bot M, Brodde M et al. FTY720, asynthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007; 115(4):501-8. (Pubitemid 46188244)
156. Keul P, Tolle M, Lucke S et al. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27(3):607-13.
157. Kahan BD. Update on pharmacokinetic/pharmacodynamic studies with FTY720 and sirolimus. Ther Drug Monit 2002; 24(1):47-52. (Pubitemid 34106731)
158. KovarikJM, SchmouderRL, Slade AJ. Overview ofFTY720 clinical pharmacokinetics and pharmacology. Ther Drug Monit 2004; 26(6):585-7. (Pubitemid 39579137)
159. Pettus BJ, Bielawski J, Porcelli AM et al. The sphingosine kinase 1/sphingosine-1-phospate pathway mediates COX-2 induction and PGE2 production in response to TNF-a. FASEB J 2003; 17:1411-21. (Pubitemid 36939148)
160. Pettus BJ, Kitatani K, Chalfant CE et al. The coordination of prostaglandin E2 production by sphingosine-1-phosphate and ceramide-1-phosphate. Mol Pharmacol 2005; 68(2):330-5. (Pubitemid 41058296)
161. Cipollone F, Fazia ML. COX-2 and atherosclerosis. J Cardiovasc Pharmacol 2006; 47(Suppl 1):S26-S36. (Pubitemid 44651782)